| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5798092 | BAYER HLTHCARE | Derivatized DTPA complexes pharmaceutical agents containing these compounds, their use, and processes for their production |
Aug, 2015
(8 years ago) | |
| US6039931 | BAYER HLTHCARE | Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production |
Nov, 2021
(2 years ago) | |
Eovist is owned by Bayer Hlthcare.
Eovist contains Gadoxetate Disodium.
Eovist has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Eovist are:
- US5798092
- US6039931
Eovist was authorised for market use on 03 July, 2008.
Eovist is available in solution;intravenous dosage forms.
Eovist can be used as magnetic resonance imaging of the liver.
Drug patent challenges can be filed against Eovist from 03 July, 2012.
The generics of Eovist are possible to be released after 13 November, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-155) | Mar 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2013 |
Drugs and Companies using GADOXETATE DISODIUM ingredient
NCE-1 date: 03 July, 2012
Market Authorisation Date: 03 July, 2008
Treatment: Magnetic resonance imaging of the liver
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
EOVIST family patents
